FOUNDER MANIFESTO · SCIENCE-FIRST · EVIDENCE-BASED MEDICINE
Most Doctors Distrust Supplements. They Are Right To.
Olympia Biosciences™ Exists to Close the Knowledge Gap Between Pharma and Nutraceuticals.
A categorical rejection of marketing-led supplementation, written by an M.Sc. Eng. in Technical Physics and Applied Mathematics (Double Specialization: Abstract Quantum Physics & Organic Microelectronics) and Ph.D. Candidate in Medical Sciences (Phlebology), who refuses to authorise what the peer-reviewed record cannot defend. This is the operating doctrine, in plain language, for clinicians and operators who treat "science-first" and "evidence-based medicine" as obligations, not slogans.
THE BUSINESS MODEL IS STRUCTURAL. THE EVIDENCE IS PUBLIC. ↓
THE FOUR PILLARS OF EVIDENCE-BASED FORMULATION
How a Composition Becomes a Defended Scientific Position.
Four independent verification layers separate an Olympia formulation from a catalogue product. Each layer is gated; a recipe that fails any one of them is rejected before tooling.
PROPRIETARY AI MODEL
Cocktail-Effect Elimination, Trained on Peer-Reviewed Literature.
AI-assisted evidence review may support literature screening; the scientific team reviews the project-specific evidence and feasibility.
SPECIALIST LEGAL REVIEW
We Only Declare What We Can Defend.
Legal and regulatory requirements are assessed for each project and intended market; any conclusions and deliverables are defined in the agreed scope.
EVIDENCE DOSSIER
Every Client Receives the Bibliography Behind the Composition.
A complete, citation-grade bibliography accompanies each formulation — drawn from PubMed-indexed Class A medical journals — documenting the published evidence that justifies every active, every dose, and every excipient choice. The composition is a hypothesis only as long as it is undocumented; once shipped, it is a defended scientific position.
STABILITY ENGINEERING
A Supplement That Oxidises in the Bottle Is a Marketing Object, Not a Therapeutic One.
Seventeen years of technical production discipline informs how we engineer stability: omega TOTOX control to keep PUFAs from oxidising, probiotic strain segregation to prevent antagonistic co-cultures, cold-chain protocols where the molecule demands them. Most factories stay silent on these failure modes. We treat them as the primary specification.
METHOD PROVES RIGOUR. WHAT FOLLOWS PROVES THE OPERATOR. ↓
ORIGIN — IN THE FOUNDER\u2019S OWN WORDS
"Many physicians are reluctant to prescribe supplements. As a Ph.D. Candidate in Medical Sciences (Phlebology), a licensed phytotherapist, and an M.Sc. Eng. in Technical Physics and Applied Mathematics (Double Specialization: Abstract Quantum Physics & Organic Microelectronics) — I understand why. There is much on this market I will not sign my name to. Olympia Biosciences was founded out of that refusal — at the intersection of medicine, technology, and a disciplined, healthy life."
— Olimpia Baranowska M.Sc. Eng. (Technical Physics & Applied Mathematics · Abstract Quantum Physics & Organic Microelectronics) · Ph.D. Candidate in Medical Sciences (Phlebology) · Founder & Scientific Director
A Founder Who Reads the Physics, the Pharmacology, and the Botany.
Olympia\u2019s scientific gates are not delegated to a contracted consultant. The technical, clinical, and botanical literacy required to refuse a flawed formulation is held inside the founder seat. 17 years of manufacturing food supplements, FSMP and related services without a single quality complaint.
PRIMARY DISCIPLINE
TECHNICAL PHYSICS
M.Sc. ENG. · GDAŃSK UNIVERSITY OF TECHNOLOGY | DOUBLE SPECIALIZATION: ABSTRACT QUANTUM PHYSICS & ORGANIC MICROELECTRONICS
CLINICAL TRACK
PHD CANDIDATE
MEDICINE · DOCTORAL STUDIES | SPECIALIZATION: PHLEBOLOGY
BOTANICAL LICENSE
CERTIFIED PHYTOTHERAPIST
LICENSED · PLANT-DERIVED PHARMACOLOGY
OPERATING RECORD
17 YRS · 0
CLIENT QA COMPLAINTS · TECHNICAL PRODUCTION
OPERATOR ESTABLISHED. NOW THE FILTER. ↓
ADMISSION GATE
We Decline More Than 80% of Inbound Mandates — Including the Most Lucrative.
Cost is optimised, never traded against quality. We choose what works — not what carries a brand premium and costs 100× more without published superiority.
Olympia is the convergence of hard business and harder science — an unobvious posture in a category dominated by white-label catalogues and dropship logistics. If you are sourcing the cheapest possible production, this is not the right intake. If you intend to put your name on a product and sleep through the night, the conversation begins here.
For clinicians and operators who treat "science-first" and "evidence-based medicine" as obligations, the work ahead is a shared intellectual mandate — and a long one.
- REJECTCHEAPEST-INPUT FORMULATIONS WHERE THE SAVING ERODES THE ACTIVE
- REJECTBRAND-PREMIUM RAW MATERIALS WHERE THE EVIDENCE IS NOT 100× THE COST
- REJECTCLAIMS THAT EFSA TOLERATES BUT THE PEER-REVIEWED RECORD DOES NOT SUPPORT
- REJECTPROJECTS WHERE COMMERCIAL VELOCITY IS ASKED TO OUTPACE SAFETY DATA
IF THE FILTER READS AS OBVIOUS, THE NEXT BLOCK IS THE INTAKE. ↓
NEXT STEP — PAID DUE DILIGENCE
If This Doctrine Reads as Obvious, You Are the Operator We Build For.
Engagement begins with a paid Discovery scope: clinical objectives, formulation thesis, and regulatory pathway are stress-tested before any production decision. The output is a defensible blueprint. The conversion is to a long shared mission — not to a quote.
RELATED INTELLIGENCE